Matrixyl 3000

Matrixyl 3000 is a cosmetic ingredient blend developed by the French company Sederma (Croda) consisting of two palmitoylated matrikine peptides: palmitoyl tripeptide-1 (Pal-Gly-His-Lys; Pal-GHK; molecular weight approximately 578 Da; the palmitoylated version of the well-characterized matrikine GHK that is the basis of GHK-Cu, KDC-MN-007) and palmitoyl tetrapeptide-7 (Pal-Gly-Gln-Pro-Arg; Pal-GQPR; molecular weight approximately 619 Da). The matrikine concept describes short bioactive peptides released by enzymatic degradation of extracellular matrix proteins (collagens, elastin, laminin) that signal to dermal fibroblasts to repair the matrix; the matrikine signal is interpreted as a tissue-damage marker that drives compensatory matrix synthesis. GHK is the canonical collagen-promoting matrikine; the GQPR sequence is derived from immunoglobulin and inhibits IL-6-induced inflammatory cytokine production. The palmitoylation of both peptides anchors them in the lipid bilayer of the stratum corneum, substantially improving topical retention relative to the unmodified peptides and providing sustained cutaneous delivery. The pharmacological argument for the blend over either peptide alone is the dual mechanism: collagen synthesis stimulation through GHK signaling combined with anti-inflammatory and matrix-protective signaling through GQPR. Published manufacturer-sponsored studies report measurable increases in skin firmness, reduced wrinkle depth, and improved skin tone at 8 weeks of twice-daily topical application of 3 percent or 4 percent Matrixyl 3000 solutions. Independent academic replication is limited. The blend is sold as a cosmetic ingredient (not a regulated drug) in essentially all major cosmetic markets. Distinct from the original Matrixyl (palmitoyl pentapeptide-4, also known as Pal-KTTKS), which is a separate Sederma matrikine ingredient.